Trial Profile

A study analyzing Frontline Combination of 3rd Generation TKI Olverembatinib and Blinatumomab for Ph+/Ph-like ALL Patients

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Blinatumomab (Primary) ; Olverembatinib (Primary)
Indications Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

15 Jun 2025 According to an Ascentage Pharma media release, data from this trial have been reported at the 2025 European Hematology Association (EHA) Annual Congress.
15 Jun 2025 Results published in the Ascentage Pharma Media Release
15 May 2024 According to an Ascentage Pharma media release, the company announced that the results from this study has been selected for Poster Presentations and to be presented at the 2024 European Hematology Association Hybrid Congress (EHA 2024).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com